Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

lined following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and InterMune's revenue is expected to continue to decline; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone may differ materially from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at http://www.intermune.com.

Actimmune(R) is a registered trademark of InterMune, Inc. Each other trademark, trade name or service mark appearing in this news release belongs to its holder.

Financial tables follow


'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... TaiGen Biotechnology Company, Limited ("TaiGen") today announced that ... leading Russian pharmaceutical company, to develop and commercialize nemonoxacin ... , Turkey and other ... novel antibiotic for the treatment of bacterial infections including ...
(Date:1/14/2014)... BURLINGAME, Calif. , Jan. 14, 2014 As pet owners ... no doubt many of them wrote: "Take better care of my ... and even designer clothes and top-brand carrying cases to take the ... Pet parents might also feel compelled to buy some pricey toys ...
(Date:1/14/2014)... In recent years, growing suspicion about the ... development and promotion has led to unprecedented levels of ... concerns about the insidious impact of commercialization of research, ... to the world’s biggest pharmas for illegal marketing activities, ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... XI,AN, China, Aug. 14 /Xinhua-PRNewswire-FirstCall/ -- Huifeng Bio-,Pharmaceutical ... and producer of plant extracts and pharmaceutical raw ... is pleased to,announce record sales and earnings for ... 2008., "In the first half of 2008, ...
... Life Sciences,Holdings, Inc. (Nasdaq: ADLS ), a ... of novel drugs in the,therapeutic areas of infection, ... for the second quarter ended June 30, 2008., ... loss for the three months was $3.4 million ...
... 14 /PRNewswire-FirstCall/ - Ondine Biopharma,Corporation (the "Company" ... medical,technology company developing photodisinfection based products, today,announced ... ended June 30, 2008., "During the ... clinical,progress with our photodisinfection technology and we ...
Cached Biology Technology:Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 2Advanced Life Sciences Announces Second Quarter 2008 Financial Results 3Advanced Life Sciences Announces Second Quarter 2008 Financial Results 4Advanced Life Sciences Announces Second Quarter 2008 Financial Results 5Advanced Life Sciences Announces Second Quarter 2008 Financial Results 6Advanced Life Sciences Announces Second Quarter 2008 Financial Results 7Advanced Life Sciences Announces Second Quarter 2008 Financial Results 8Advanced Life Sciences Announces Second Quarter 2008 Financial Results 9Advanced Life Sciences Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 2Ondine Biopharma Announces Second Quarter 2008 Financial Results 3Ondine Biopharma Announces Second Quarter 2008 Financial Results 4Ondine Biopharma Announces Second Quarter 2008 Financial Results 5Ondine Biopharma Announces Second Quarter 2008 Financial Results 6Ondine Biopharma Announces Second Quarter 2008 Financial Results 7Ondine Biopharma Announces Second Quarter 2008 Financial Results 8Ondine Biopharma Announces Second Quarter 2008 Financial Results 9Ondine Biopharma Announces Second Quarter 2008 Financial Results 10Ondine Biopharma Announces Second Quarter 2008 Financial Results 11Ondine Biopharma Announces Second Quarter 2008 Financial Results 12Ondine Biopharma Announces Second Quarter 2008 Financial Results 13Ondine Biopharma Announces Second Quarter 2008 Financial Results 14Ondine Biopharma Announces Second Quarter 2008 Financial Results 15Ondine Biopharma Announces Second Quarter 2008 Financial Results 16Ondine Biopharma Announces Second Quarter 2008 Financial Results 17
(Date:7/9/2014)... can alleviate the symptoms of Alzheimer,s disease, ... and effectively scavenge amyloid beta peptide in ... reduced and eliminated Aβ deposition in an ... significantly improved behavioral and cognitive impairment. Dr. ... Hospital of China Medical University, China immunized ...
(Date:7/9/2014)... high levels of vitamin D in their blood are more ... Patients with the highest levels of vitamin D have half ... levels, the findings reveal. , The study is the first ... cancer patients after their diagnosis which includes that produced ... with their long term survival prospects. , The ...
(Date:7/9/2014)... first make a copy of its DNA, a fundamental step ... times a day in the human body. While scientists have ... to replicate DNAthe enzymes that unzip the double-stranded DNA and ... how the process works. , Now, researchers at Rockefeller University ... on at the "replication fork"the point where DNA is split ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4
... studying the reliability of species distribution models for ... have focused their research on the endangered marsupial, ... Ecography demonstrates that studying weather events, rather ... a clearer insight into the Bettong,s movements, range ...
... BRUNSWICK, N.J. The National Institutes of Health (NIH) ... quick and economical analysis of tissue from breast cancer ... a common form of breast cancer is likely to ... minimize side effects. The NIH made its grant ...
... Large, persistent populations of genetically engineered canola ... North Dakota. As genetically engineered crops become increasingly ... potential ecological side effects. A study published ... reports that genetically engineered canola endowed with ...
Cached Biology News:Australia's endangered bettong reveals how weather effects species distribution 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 2Rutgers-affiliated company receives funding for technology to help choose breast cancer treatments 3